UCB UCB.BR
UCB is a Belgian biopharmaceutical company that develops and commercializes innovative medicines, primarily in the areas of neurology and immunology. UCB shows exceptional growth (earnings +134.8%) and solid financial health (ND/EBITDA 0.84), but US regulatory pressure on drug pricing and negative momentum (-13.55%) temper the appeal of its valuation (P/E 18.99).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
UCB is a Belgian biopharmaceutical company that develops and commercializes innovative medicines, primarily in the areas of neurology and immunology. UCB shows exceptional growth (earnings +134.8%) and solid financial health (ND/EBITDA 0.84), but US regulatory pressure on drug pricing and negative momentum (-13.55%) temper the appeal of its valuation (P/E 18.99).
Score by category
| Category | Score |
|---|---|
| Financial health | 7.7 |
| Quality / Moat | 7.3 |
| Valuation | 5.6 |
| Growth | 8.8 |
| Dividend | 3.6 |
| Momentum | 1.0 |
| Risk & Context | 8.4 |
OVERALL SCORE: 6.6/10
Context and risks
US regulatory pressure on drug pricing (MFN and Medicaid agreements) directly affects its main market. Additionally, rising interest rates make debt financing more expensive, although its leverage is low.
News considered in the analysis
- UCB (UCBJY) Upgraded to Buy: Here's Why — Upgrade de analista que refleja el momentum positivo del negocio, aunque su impacto directo en valoración es limitado.
- Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers — La ampliación de la política de nación más favorecida (MFN) a más farmacéuticas, incluida UCB, podría presionar los precios de sus medicamentos en EE.UU., su mercado clave.
- Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms — Los acuerdos de precios de Medicaid podrían implicar descuentos para algunos de sus fármacos, afectando ligeramente los ingresos en EE.UU.
- UCB SA (UCBJF) (H1 2026) Earnings Call Highlights: Record Sales and Strategic Expansion Drive ... — Resultados récord en ventas y expansión estratégica confirman la fortaleza operativa y el crecimiento del negocio.
- Is It Too Late To Consider UCB (ENXTBR:UCB) After A 195% Three Year Surge? — Artículo de opinión sobre la revalorización pasada, sin información nueva relevante.
Verdict: Hold, with attention to US regulatory developments and the ability to sustain earnings growth.
Main risk: US regulatory pressure on drug pricing (MFN policy and Medicaid agreements) is the biggest risk for UCB, given that its main market is the US.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →